UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for ovarian cancer in the United Kingdom. Explore treatment pathways including surgery, chemotherapy, PARP inhibitors, and maintenance therapy.
Ovarian cancer affects ~7,500 women per year in the UK. It is often diagnosed at a late stage because early symptoms (bloating, abdominal pain, feeling full quickly) are vague. The most common type is high-grade serous carcinoma (~70%). Survival has improved with the introduction of PARP inhibitors and anti-angiogenic therapy, particularly for BRCA-mutated tumours.
All ovarian cancer patients should be offered genetic testing for BRCA1, BRCA2, and other homologous recombination repair (HRR) gene mutations. ~15-20% of ovarian cancers have BRCA mutations, and ~25% have HRR deficiencies. BRCA-mutated tumours respond particularly well to PARP inhibitors (olaparib, niraparib, rucaparib). Testing also identifies families who may benefit from cancer screening programmes.
Standard treatment is surgery (debulking) followed by platinum-based chemotherapy (carboplatin + paclitaxel). Maintenance therapy is now standard: bevacizumab (anti-VEGF) for most patients, PARP inhibitors (olaparib or niraparib) especially for BRCA-mutated or HRD-positive tumours. For recurrent disease: if platinum-sensitive (>6 months since last chemo), rechallenge with platinum + PARP inhibitor. If platinum-resistant, options include weekly paclitaxel, liposomal doxorubicin, or clinical trials.
Active UK ovarian cancer trials include: antibody-drug conjugates (mirvetuximab soravtansine for FRα-positive), bispecific antibodies, new PARP inhibitor combinations, immunotherapy combinations, and cancer vaccines. The NHS ovarian cancer audit is improving care standards nationwide.
Free AI-powered matching - no signup required
Search epithelial ovarian cancer Trials →